Showing 1 - 10 of 83
Regulatory compliance in unprecedented times: how to adapt but stay on track - a guide for the European life sciences industry
The COVID-19 pandemic has had an unprecedented impact on stakeholders in the UK and EU’s life sciences industry - from companies, to third parties, governments, regulators and insurers.
We are pleased to announce that the publication of the 2021 edition of The Legal 500 Europe, Middle East and Africa has seen us build on our 2020 achievements.
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds, but, behind the headlines, how is the pandemic affecting attitudes to risk?
The outcome of two Canadian product class actions in 2020 signal hurdles claimants may face around the globe in 2021 in alleging adverse health effects in mass tort claims involving products for consumption such as medical cannabis, other pharmaceutical products and food.
This report examines the key features of the Directive of the European Parliament and of the European Council on representative actions for the protection of the collective interests of consumers and its wider impact on consumer-led litigation across Europe, including comparative insights into national class action mechanisms in the United Kingdom, Belgium, Denmark, France, Portugal, Spain and Ireland.
While 2020 was undoubtedly the year of the COVID-19 pandemic, 2021 is becoming the year of the vaccination. In this article, our industry experts consider the latest developments relating to the vaccine and provide an overview of its impact on various sectors.
On the surface, the London Market enters 2021 looking very different to its 2020 version. Underwriting rooms lay empty, offices unoccupied, pubs eerily quiet. But beyond the physical stillness, this world leading hub has not paused for breath. Digital systems and solutions have taken centre stage as the London Market has responded to a seismic shift in working patterns and insurance risks.
Despite welcome news of several viable vaccines in production, having been approved for emergency use globally, the race to develop protections against and treatments for COVID-19 is far from over. Alongside the approved vaccines, there are more than 250 potential vaccines at various stages of development. These vaccines will require worldwide roll out in order to contain and protect against the continued spread of COVID-19.
Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare.